All stock lists
Unlock the score
Nuo Therapeutics, Inc. (OTC:AURX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.30+0.00 (+0.00%)
Market cap
$63.0M
Insider Score
Health Score
Listed since
Oct 24, 2017
Website
Insider Score
/ 100
AURX Insider Score
Nuo Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
AURX Stock Insider Trading Activity
AURX stock’s insider trading shows 2 purchases for an estimated $9.54K by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days2 qualifying buys1 insider$9.54K bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| JORDEN DAVID EMERSON CEO | Buy | 7,984 | $1.09 | $8.69K | 0.4% | 2,070,000 | Aug 28, 2026 | CCFO Buy | Form 4 |
| JORDEN DAVID EMERSON CEO | Award | 7,984 | $1.09 | $8.69K | 0.4% | 2,070,000 | Aug 28, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Buy | 789 | $1.07 | $844.23 | 0.0% | 2,062,016 | Aug 27, 2026 | CFirst BuyCFO Buy | Form 4 |
| JORDEN DAVID EMERSON CEO | Award | 789 | $1.07 | $844.23 | 0.0% | 2,062,016 | Aug 27, 2026 | — | Form 4 |
| Pittman Scott M. Director | Tax withheld | 39,604 | $1.01 | $40.00K | 0.7% | 5,400,396 | Jun 30, 2026 | — | Form 4 |
| WINZER C ERIC Director | Option exercise | 40,000 | $1.00 | $40.00K | 23.2% | 212,654 | Jun 30, 2026 | — | Form 4 |
| WINZER C ERIC Director | Tax withheld | 39,604 | $1.01 | $40.00K | 18.6% | 173,050 | Jun 30, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Option exercise | 162,500 | $1.00 | $162.50K | 7.9% | 2,222,119 | Jun 30, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Tax withheld | 160,892 | $1.01 | $162.50K | 7.2% | 2,061,227 | Jun 30, 2026 | — | Form 4 |
| Pittman Scott M. Director | Option exercise | 40,000 | $1.00 | $40.00K | 0.7% | 5,440,000 | Jun 30, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Award | 13,245 | $1.10 | $14.51K | 0.6% | 2,085,000 | Jun 5, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Option exercise | 125,000 | $0.40 | $50.00K | 6.4% | 2,071,755 | Jan 1, 2026 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Tax withheld | 25,381 | $1.97 | $50.00K | 1.2% | 2,046,374 | Jan 1, 2026 | — | Form 4 |
| WINZER C ERIC Director | Option exercise | 68,750 | $0.40 | $27.50K | 58.4% | 186,404 | Dec 17, 2025 | — | Form 4 |
| WINZER C ERIC Director | Tax withheld | 13,750 | $2.00 | $27.50K | 7.4% | 172,654 | Dec 17, 2025 | — | Form 4 |
| Mintz Paul Director | Tax withheld | 9,091 | $2.20 | $20.00K | 7.7% | 108,294 | Dec 9, 2025 | — | Form 4 |
| Mintz Paul Director | Option exercise | 50,000 | $0.40 | $20.00K | 74.2% | 117,385 | Dec 9, 2025 | — | Form 4 |
| JORDEN DAVID EMERSON CEO | Sell | 200,000 | $1.50 | $300.00K | 9.3% | 1,946,755 | Nov 28, 2025 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Sell (S) — Open-market or private sale
- Award (A) — Grant or award from the company, not a purchase
- Tax withheld (F) — Shares withheld to pay tax or an exercise price
- Option exercise (M) — Exercise or conversion of an exempt derivative
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.